Acurx Pharmaceuticals (NASDAQ:ACXP) Price Target Raised to $31.00 at HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP) had its price objective raised by equities researchers at HC Wainwright to $31.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q3 2025 earnings at ($1.61) EPS, Q4 2025 earnings at ($1.69) EPS, FY2025 earnings at ($7.14) EPS, FY2026 earnings at ($6.03) EPS and FY2027 earnings at ($4.83) EPS.

Separately, Wall Street Zen raised Acurx Pharmaceuticals to a “sell” rating in a research note on Saturday, August 9th.

Acurx Pharmaceuticals Stock Up 3.0%

Shares of ACXP stock traded up $0.14 during trading hours on Tuesday, hitting $4.86. 65,873 shares of the company’s stock were exchanged, compared to its average volume of 141,149. The firm has a market cap of $7.47 million, a P/E ratio of -0.45 and a beta of -1.27. The firm has a 50 day moving average of $8.48 and a two-hundred day moving average of $9.43. Acurx Pharmaceuticals has a fifty-two week low of $3.80 and a fifty-two week high of $47.80.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings data on Monday, August 11th. The company reported ($1.89) EPS for the quarter, beating the consensus estimate of ($2.00) by $0.11. On average, equities analysts forecast that Acurx Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Acurx Pharmaceuticals

Several institutional investors have recently bought and sold shares of ACXP. Vanguard Capital Wealth Advisors purchased a new position in shares of Acurx Pharmaceuticals in the 1st quarter valued at about $26,000. O Brien Greene & Co. Inc acquired a new position in shares of Acurx Pharmaceuticals in the second quarter valued at approximately $31,000. Prospect Financial Services LLC grew its holdings in Acurx Pharmaceuticals by 11.4% during the first quarter. Prospect Financial Services LLC now owns 366,576 shares of the company’s stock worth $143,000 after acquiring an additional 37,500 shares during the period. Finally, Armistice Capital LLC purchased a new stake in Acurx Pharmaceuticals during the second quarter worth $551,000. 11.53% of the stock is owned by institutional investors and hedge funds.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.